# Tetra Bio-Pharma signs manufacturing agreement with Vitiprints for CAUMZ and HCC011

Tetra Bio-Pharma signed a definitive manufacturing agreement with Vitiprints LLC for commercial scale production of CAUMZ and HCC011 using Vitiprints' patented 2D printing technology. The agreement includes an exclusive license and milestone/royalty payments.

- Type: Contract
- Announced: 2020-02-13
- Where: Moncton, Canada, Canada
- Status: announced
- Capacity: 100,000 CAUMZ dosage units per 8-hour shift
- Products: cannabinoid-derived drugs, CAUMZ, HCC011
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Tetra Bio-Pharma](https://endata.com/companies/45250.md)
- [Vitiprints](https://endata.com/companies/45251.md) (supplier)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2020/02/13/1984695/0/en/Tetra-Bio-Pharma-Enters-into-Manufacturing-Agreement-with-Vitiprints-LLC-for-CAUMZ-and-HCC011.html), 2020-02-13: "Tetra Bio-Pharma today announced it has signed a definitive manufacturing agreement with Vitiprints LLC, for the commercial scale production of CAUMZ and HCC011."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.